BioSpace News Archive

Enveric Biosciences announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results.

Endologix LLC announces that the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through Payment for the DETOUR System, effective January 1, 2024.

Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

SELLAS Life Sciences Group, Inc. announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S, combined with the checkpoint inhibitor nivolumab in patients with refractory/relapsed malignant pleural mesothelioma.

McKesson Corporation will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024.

Diversified biotechnology company CCM Biosciences announced the launch of its business unit CCM 5Prime Sciences focused on the development and application of proprietary technology in the domain of DNA biotechnology.

Kuros Biosciences, a leader in next generation bone graft technologies, announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV.

First Wave BioPharma, Inc. announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $5.50 per share, in exchange for new warrants as described below.

ResMed announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. at the Westin St. Francis in San Francisco, CA.